(Total Views: 1245)
Posted On: 06/24/2019 10:34:05 AM
Post# of 96
IT’S HARD TO OVERSTATE HOW HOT IMMUNOTHERAPY IS RIGHT NOW
Harnessing the body’s immune system to fight cancers – immuno-oncology in medical jargon – has been on the rapid rise recently.
Some major success stories have shown immunotherapies to be a far more targeted avenue for treating cancer, and as one article put it, “It’s hard to overstate how hot immunotherapy is right now.”
Just this month, billionaire Silicon Valley veteran Sean Parker, made international headlines when he announced a US$250mln donation in support of immunotherapy research. Parker, who founded the peer-to-peer music file sharing network Napster and who was once president of social media giant Facebook, has created six major immunotherapy centers as a part of the “Parker Institute for Cancer Immunotherapy”, and will include more than 40 laboratories employing in excess of 300 researchers.
According to Parker’s web site, the money will be used to form “an Immunology Research Dream Team dedicated to cancer immunology”. Interestingly, hospitals featured alongside Vaxil on MCTV, will be recipients of Parker’s donation, including Memorial Sloan Kettering and MD Anderson Cancer Center.
VAXIL FOCUSED ON IMMUCIN’S MOST IMPORTANT TEST YET
As for Vaxil, it recently listed on the TSX-Venture with the ticker symbol VXL. The company is now focused on its major upcoming Phase-II clinical trial, ImMucin’s most important test yet.
“Our next clinical trial, a robust Phase-II, has potential to catapult our company is set to include patients with very good partial response, and MRD [minimal residual disease] positive post-first line of therapy, and we hope it will drive us into a pivotal phase III [trial], possibly with a big pharma partner,” Dr Carmon revealed.
Harnessing the body’s immune system to fight cancers – immuno-oncology in medical jargon – has been on the rapid rise recently.
Some major success stories have shown immunotherapies to be a far more targeted avenue for treating cancer, and as one article put it, “It’s hard to overstate how hot immunotherapy is right now.”
Just this month, billionaire Silicon Valley veteran Sean Parker, made international headlines when he announced a US$250mln donation in support of immunotherapy research. Parker, who founded the peer-to-peer music file sharing network Napster and who was once president of social media giant Facebook, has created six major immunotherapy centers as a part of the “Parker Institute for Cancer Immunotherapy”, and will include more than 40 laboratories employing in excess of 300 researchers.
According to Parker’s web site, the money will be used to form “an Immunology Research Dream Team dedicated to cancer immunology”. Interestingly, hospitals featured alongside Vaxil on MCTV, will be recipients of Parker’s donation, including Memorial Sloan Kettering and MD Anderson Cancer Center.
VAXIL FOCUSED ON IMMUCIN’S MOST IMPORTANT TEST YET
As for Vaxil, it recently listed on the TSX-Venture with the ticker symbol VXL. The company is now focused on its major upcoming Phase-II clinical trial, ImMucin’s most important test yet.
“Our next clinical trial, a robust Phase-II, has potential to catapult our company is set to include patients with very good partial response, and MRD [minimal residual disease] positive post-first line of therapy, and we hope it will drive us into a pivotal phase III [trial], possibly with a big pharma partner,” Dr Carmon revealed.
(0)
(0)
